powerwalker Monday, 02/15/21 04:21:42 PM Re: McMagyar post# 298568 Post # of 310102 Mc, here's a thought that might have some validity. At this time last year, Anavex announced that it had hit the 50% enrollment on the AD P2b/3 trial (225 out of the 450 planned) and it was moving forward with trial sites in other countries. So, those 225 participants are now passed the 48-week trial period and data has been gathered. What if ... the TGA wants to take that data, along data from Rett, RDD and AD P2a trials, and examine all to determine whether there might be something to this blarcamesine and then, if it believes all of this positive data is sufficient to approve 2-73 outright, or at least, a P4 trial with commercialization of it, thus not waiting for another 18 months for P2b/3 to be completed and analyzed? I think the Aussie know they have waited long enough to give the "Go-ahead" to our little engine that could to help it with its health costs. IMO, though maybe a trifle naivé. ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!